Mapping of the IgM and IgG antibody responses to Talaromyces marneffei infection in mice and humans - Deciphering acute from reactivated or latent infections

小鼠和人类对马尔尼菲踝节菌感染的 IgM 和 IgG 抗体反应图谱 - 区分急性感染和潜伏感染

基本信息

  • 批准号:
    10327068
  • 负责人:
  • 金额:
    $ 23.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-06-22 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

Abstract Talaromycosis is an invasive mycosis caused by the dimorphic fungus Talaromyces marneffei (Tm) endemic in Southeast Asia. Infection kills one in three infected people with a compromised immune system, and is the leading causes of HIV-associated death in the endemic region. Current diagnostics can only identify the fungus in late stage infection. We know infection can reactivate up to 7 years from exposure in returning travelers, but we lack an antibody test to determine who has been infected and who has a primary versus a reactivated infection. We and other have documented a 30-70% increase in cases during the rainy humid months in multiple countries. Our epidemiology studies suggest that this remarkable seasonality is due to acute exposure leading to acute primary infections rather than alterations in host factors. Our human cohorts, including the IVAP clinical trial, have shown that patients who present with an acute pulmonary syndrome have a shorter duration of illness and rapidly progressive fatality. Our central hypothesis is that the acute pulmonary form of infection has a more virulent pathogenesis than the reactivated form, and host IgM and IgG patterns can differentiate between these forms. We propose two related but independent aims to test this hypothesis. AIM 1. To validate the novel anti-Mp1p IgM and IgG enzyme immunoassay (EIA) and to delineate the impact of acute primary infection on patient outcomes. Here, we will leverage the IVAP trial biorepository with longitudinal plasma samples (6 timepoints collected over 24 weeks) from 440 culture-confirmed talaromycosis patients to map the IgM and IgG responses in humans, identify the IgM/IgG serological pattern associated with acute infection, and determine the impact of acute primary infection on patient outcomes. AIM 2. To develop a novel murine pulmonary model to decipher the host anti-Tm antibody responses to primary versus reactivated infection. Here, we will develop a novel pulmonary model using non-invasive oropharyngeal aspiration and low infection inoculum to mimic natural human infection. We will develop an acute primary infection model in CD4-depleted mice and develop chronic infection in immunocompetent mice, followed by CD4 depletion to induce a reactivated infection model. Our goal is to understand how a mammalian antibody response should differ between primary versus reactivated infection and use the mouse antibody data to strengthen the interpretation of antibody responses in humans. Impact. Our studies aim to establish a serological diagnosis for talaromycosis which has the potential to differentiate acute from reactivated infection and expand our knowledge of disease spectrum. The new murine pulmonary model will facilitate new research into the host immune response to Tm infection. The antibody test will enable population-based seroprevalence studies to advance our understanding of disease burden, geographic risk, latency, and risk populations. This knowledge will inform both disease management at the individual level and prevention strategies at the population level.
抽象的 踝节菌病是一种侵袭性真菌病,由马尔尼菲踝节菌 (Tm) 引起,流行于 东南亚。感染导致三分之一免疫系统受损的感染者死亡,并且是 流行地区艾滋病毒相关死亡的主要原因。目前的诊断只能识别真菌 处于感染晚期。我们知道,回国旅客接触病毒后长达 7 年内可能会重新激活感染,但是 我们缺乏抗体测试来确定谁已被感染以及谁患有原发性感染和重新激活性感染 感染。我们和其他人记录了多个地区的多雨潮湿月份病例增加了 30-70% 国家。我们的流行病学研究表明,这种显着的季节性是由于急性暴露导致 急性原发感染而不是宿主因素的改变。我们的人类队列,包括 IVAP 临床 试验表明,患有急性肺综合征的患者病程较短 和迅速进展的死亡。我们的中心假设是,急性肺部感染的发病率更高。 比重新激活的形式具有更强的致病机制,并且宿主 IgM 和 IgG 模式可以区分这些 形式。我们提出两个相关但独立的目标来检验这一假设。 目的 1. 验证新型抗 Mp1p IgM 和 IgG 酶联免疫分析 (EIA) 并描述 急性原发感染对患者预后的影响。在这里,我们将利用 IVAP 试验生物样本库 来自 440 名培养确认的纵向血浆样本(24 周内收集的 6 个时间点) 踝部真菌病患者绘制人类 IgM 和 IgG 反应图谱,识别 IgM/IgG 血清学模式 与急性感染相关,并确定急性原发感染对患者预后的影响。 目的 2. 开发一种新型小鼠肺部模型来破译宿主抗 Tm 抗体对 原发感染与再激活感染。在这里,我们将使用非侵入性开发一种新型肺部模型 口咽抽吸和低感染接种物模仿自然人类感染。我们将开发一种敏锐的 在 CD4 缺失的小鼠中建立原发感染模型,并在免疫功能正常的小鼠中形成慢性感染,随后 通过 CD4 耗竭诱导重新激活的感染模型。我们的目标是了解哺乳动物抗体如何 原发感染与再激活感染之间的反应应有所不同,并使用小鼠抗体数据来确定 加强对人类抗体反应的解释。 影响。我们的研究旨在建立踝部真菌病的血清学诊断,这有可能 区分急性感染和再激活感染并扩大我们对疾病谱的了解。新的小鼠 肺部模型将促进宿主对 Tm 感染免疫反应的新研究。抗体测试 将使基于人群的血清流行率研究能够增进我们对疾病负担的理解, 地理风险、潜伏期和风险人群。这些知识将为疾病管理提供信息 个人层面和人口层面的预防策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Thuy Le其他文献

Thuy Le的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Thuy Le', 18)}}的其他基金

Tropical Medicine Research Center for Talaromycosis in Vietnam
越南踝部真菌病热带医学研究中心
  • 批准号:
    10444448
  • 财政年份:
    2022
  • 资助金额:
    $ 23.24万
  • 项目类别:
Tropical Medicine Research Center for Talaromycosis in Vietnam
越南踝部真菌病热带医学研究中心
  • 批准号:
    10598580
  • 财政年份:
    2022
  • 资助金额:
    $ 23.24万
  • 项目类别:
Mapping of the IgM and IgG antibody responses to Talaromyces marneffei infection in mice and humans - Deciphering acute from reactivated or latent infections
小鼠和人类对马尔尼菲踝节菌感染的 IgM 和 IgG 抗体反应图谱 - 区分急性感染和潜伏感染
  • 批准号:
    10436393
  • 财政年份:
    2021
  • 资助金额:
    $ 23.24万
  • 项目类别:
Making an early diagnosis of talaromycosis - an approach to reduce morbidity and mortality in advanced HIV disease in Southeast Asia
对踝部真菌病进行早期诊断——一种降低东南亚晚期艾滋病毒发病率和死亡率的方法
  • 批准号:
    9978703
  • 财政年份:
    2019
  • 资助金额:
    $ 23.24万
  • 项目类别:
Making an early diagnosis of talaromycosis - an approach to reduce morbidity and mortality in advanced HIV disease in Southeast Asia
对踝部真菌病进行早期诊断——一种降低东南亚晚期艾滋病毒发病率和死亡率的方法
  • 批准号:
    10190805
  • 财政年份:
    2019
  • 资助金额:
    $ 23.24万
  • 项目类别:
Making an early diagnosis of talaromycosis - an approach to reduce morbidity and mortality in advanced HIV disease in Southeast Asia
对踝部真菌病进行早期诊断——一种降低东南亚晚期艾滋病毒发病率和死亡率的方法
  • 批准号:
    10426172
  • 财政年份:
    2019
  • 资助金额:
    $ 23.24万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了